Aims/hypothesis. There is increasing evidence that hyperinsulinaemia is linked with the development of atherosclerosis in patients with diabetes. However, the mechanisms by which hyperinsulinaemia causes accelerated atherosclerosis, especially with respect to leukocytes transendothelial migration, are poorly understood. We examined whether hyperinsulinaemia directly affects neutrophil transendothelial migration and surface expression of related endothelial adhesion molecules. Methods. Experiments on the transmigration of neutrophils from healthy volunteers and from patients with Type II (non-insulin-dependent) diabetes mellitus across human umbilical vein endothelial cells cultured in insulin-rich medium using cell-culture inserts were carried out. Migrated neutrophils were quantified by measuring their myeloperoxidase activities, and the surface expression of endothelial adhesion molecules was examined using an enzyme immunoassay. Results. High insulin (over 50 µU/ml for 24 h) enhanced neutrophil transendothelial migration in a dose-dependent manner. This was associated with increased expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) but not of intercellular adhesion molecule-1 (ICAM-1), P-selectin or E-selectin. Both phenomena were attenuated by pretreatment with a tyrosine kinase inhibitor, especially a mitogenactivated protein kinase inhibitor, but not by inhibitors of other second messengers. In addition, a mitogenactivated protein kinase activator, anisomycin, by itself enhanced both neutrophil transendothelial migration and PECAM-1 expression within 3 h in a dosedependent manner. Pretreatment with nitric oxide synthase inhibitors had no effect on these events. Conclusion/interpretation. These results suggest that hyperinsulinaemia could accelerate atherosclerosis by directly enhancing neutrophil transendothelial migration through increasing endothelial PECAM-1 expression via mitogen-activated protein kinase activation.
lar complications, but has little effect on macrovascular complications including AMI [6, 7, 8] . These results further support the idea that hyperinsulinaemia, but not hyperglycaemia, influences the increased development of AMI and stroke in patients with diabetes. Understanding the mechanisms linking hyperinsulinaemia with accelerated atherosclerosis could be helpful in preventing excessive atherosclerotic complications in diabetic patients.
Recently, inflammation in the vascular wall has emerged as a major culprit in the development of atherosclerosis [9] . Although the crucial early events in vascular inflammation in atherosclerosis are the adhesion and transendothelial migration of leukocytes, especially neutrophils, which are the first immune cells to arrive at the inflammatory site, seem to play important roles in the initiation of both events [10] . In addition, recent reports suggested that neutrophils were occasionally found in disrupted plaques [11] , and myeloperoxidase (MPO), the enzyme of leukocytes (including neutrophils) which promotes oxidation of lipoproteins, was present in atherosclerotic plaques [12] . These observations support the importance of neutrophil transendothelial migration in the development and disruption of atherosclerotic plaques [13] . Therefore, we focused on the correlation between hyperinsulinaemia and neutrophil transendothelial migration.
It is well known that leukocyte transendothelial migration is regulated by several endothelial adhesion molecules, especially platelet endothelial cell adhesion molecules-1 (PECAM-1). A number of studies showed that an antibody against PECAM-1 blocked the transendothelial migration of leukocytes into inflammatory sites [14, 15] and that PECAM-1-deficient mice had defective neutrophil transendothelial migration [16] . PECAM-1 is a 130-kD member of the immunoglobulin gene superfamily and is expressed constitutively on endothelial cell surfaces [14] . We therefore investigated whether high insulin changes PECAM-1 expression on endothelial cell surfaces and its correlation with neutrophil transendothelial migration.
Many reports indicate that insulin has two different activities. It can be either atherogenic through a mitogen-activated protein (MAP) kinase pathway or antiatherogenic through a phosphatidylinositol-3 (PI-3) kinase pathway which promotes the production of the vasodilator nitric oxide by endothelial cells [17, 18, 19] . We have reported previously that high insulin enhances neutrophil-endothelial cell adhesion through a protein kinase C (PKC) and MAP kinase pathways [20] . Based on these data, we evaluated the intracellular mechanisms, including the participation of nitric oxide, associated with high insulin-mediated neutrophil transendothelial migration and surface expression of endothelial PECAM-1.
Materials and methods
This study was carried out in accordance with the Declaration of Helsinki as revised in 1996.
Cell culture. Human umbilical vein endothelial cells (HUVEC; Kurabo, Osaka, Japan) were cultured in 25 cm 2 collagen I-coated flasks (Becton and Dickinson, Bedford, Mass., USA) at 37°C in a 100% humidified atmosphere containing 5% CO 2 , and expanded after brief trypsinization using 0.25% trypsin in PBS containing 0.02 % EDTA. Cells were cultured in CS-C medium (45% DMEM, 45 % Ham's F12 medium, 10% foetal bovine serum, 10 ng/ml acidic-fibroblast growth factor, 50 U/ml heparin, and 15 mmol/l HEPES; Cell Systems, Kirkland, Wash., USA) containing antibiotic-antimicotic (Gibco BRL, Grand Island, N.Y., USA). Culture medium was replaced twice weekly, and cells were subcultured when confluent. Passage 4 cells were used for all the experiments.
Neutrophil isolation. This study protocol was approved by the ethics committee in Kasadera Hospital, Nagoya, Japan. After informed consent, human neutrophilic polymorphonuclear leukocytes (PMN) were isolated from venous blood of healthy non-smoking volunteers and Type II diabetic patients with hyperinsulinaemia in Kasadera Hospital using standard dextran sedimentation and gradient separation on Histopaque 1077 (Sigma, St. Lois, Mo., USA). This procedure yields a PMN population which is 98% pure as judged by acetic acid-crystal violet staining and 95 to 98% viable by trypan blue exclusion. No platelet contamination was seen in the isolated PMN examined using a microscope.
Assay of neutrophil transmigration across HUVEC.
A neutrophil transendothelial migration assay was done according to a method described previously [21] with a minor modification. For transmigration experiments, HUVEC were cultured on human fibronectin-coated cell culture inserts (3.0 µm pore size; Becton Dickinson, Bedford, Mass., USA) in 24-well plates. They were incubated for 24 to 72 h at 37°C with or without human regular insulin (Novolin R, Novo-Nordisk, Bagsvaard, Denmark) and/or various chemical agents. The surface area of each insert was 0.33 cm 2 , containing approximately 16 000 endothelial cells. After treatment, culture medium in both the inserts and wells was replaced with Hanks' balanced salt solution (HBSS, Gibco BRL), and neutrophils (exactly 1×10 5 cells) were added to each upper compartment (insert) and allowed to migrate across HUVEC monolayers to the lower compartment (well) for 1 h at 37°C. To stimulate neutrophil migration, a chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (10 -7 mol/l, Sigma) was added to the lower compartments before adding neutrophils. Neutrophil migration was stopped by removing the inserts from the wells and then the 24-well plates were centrifuged at 1500 rpm for 5 min. Migrated neutrophils in the wells were quantified with a myeloperoxidase (MPO) assay using a previously reported method [20] in which the H 2 O 2 -dependent oxidation of 3,3′,5,5′-tetramethylbenzidine (Sigma) was measured. Neutrophil migration was expressed as the ratio of MPO activity of migrated neutrophils to that of the total neutrophils (1×10 5 
cells).
Assay of surface expression of endothelial PECAM-1. Surface expression of endothelial PECAM-1 was measured using a method reported previously [20] . Briefly, after treatment of cells with or without human regular insulin in collagen I-coated 24-well plates, cells were fixed for 10 min at room temperature with 1% paraformaldehyde in PBS. After three washes with 1 ml HBSS:PBS (1:1), cells were incubated for 60 min at 37°C with an anti-PECAM-1 antibody (Ab) (primary antibody; diluted 1:100; Sigma) in HBSS:PBS containing 5% foetal calf serum (FCS). Cells were washed twice with 0.5 ml HBSS:PBS and incubated for 60 min at 37°C with horseradish peroxidaseconjugated goat anti-mouse IgG (diluted 1:2500; Sigma) in HBSS:PBS containing 5% FCS. Cells were then washed three times with 0.5 ml HBSS:PBS and incubated for 60 min at 37°C in the dark with 0.25 ml 0.003% H 2 O 2 plus 0.1 mg/ml 3,3′, 5,5′-tetramethylbenzidine as a substrate. The reaction was stopped by adding 75 µl of 8 N H 2 SO 4 , and the samples were transferred to 96-well plates which were read at 450 nm on a plate reader. Controls consisted of cells stained only with secondary antibody.
Immunoblotting. The expression of endothelial PECAM-1 phosphorylation was analysed using a Western blotting method. After treatment of cells with or without human regular insulin in collagen I-coated 6 cm tissue culture dishes (Becton and Dickinson, Bedford, Mass., USA), cells were lysed with a lysis buffer containing 50 mmol/l Tris-HCl pH 7.5, 120 mmol/l NaCl, 2 mmol/l EGTA, 10 mmol/l NaF, 40 mmol/l β-glycerophosphate, 1% Triton X-100, 1 mmol/l dithiothreitol, 10 µg/ml aprotinin, and 1 mmol/l phenylmethylsulfonyl fluoride. The lysates were centrifuged at 15 000 rpm for 20 min at 4°C. Proteins in the lysates were separated in 6% sodium dodecyl sulphate-polyacrylamide gels (SDS-PAGE) and transferred to nitrocellulose membranes (Amersham) according to standard procedures. The membranes were blocked overnight with 5% non-fat milk containing 0.05% Tween 20 in PBS. To detect the expression of PECAM-1 phosphorylation, the membranes were incubated for 1 h at room temperature with anti-phosphotyrosine Ab (4G10) (primary antibody; diluted 1:5000; Upstate Biotechnology, Lake Placid, N.Y., USA) followed by horseradish-peroxidase-conjugated goat anti-mouse IgG Ab (secondary Ab; diluted 1:5000; Upstate Biotechnology, Lake Placid, N.Y., USA). Antibody binding was detected using the enhanced chemiluminescence detection system (Amersham) according to the manufacturer's instructions.
Treatment protocols. Before a transmigration or surface expression assay, HUVEC monolayers were preincubated for 3 h with or without the following agents; intracellular second messenger inhibitors: a classical protein kinase C (PKC) inhibitor, Gö6976 (10 nmol/l; Calbiochem, San Diego, Calif., USA), a broad PKC inhibitor, Gö6983 (0.1 µmol/l, Calbiochem), an intracellular calcium chelator, 3,4,5-trimethoxybenzoic acid 8-(diethyamino)-octyl ester (TMB-8) (0.1 mmol/l; Sigma), a protein kinase G (PKG) inhibitor, KT5823 (0.5 µmol/l; Calbiochem), a tyrosine kinase inhibitor, genistein (5 µmol/l; Calbiochem), a protein kinase A (PKA) inhibitor, N-[2-(p-bromo-cinnamylamino) ethyl]-5-isoquinolinesulfomide·2HCL (H-89) (0.1 µmol/l; Seikagaku, Tokyo, Japan), a MAP kinase inhibitor, PD98059 (10 µmol/l; Calbiochem), and a PI 3-kinase inhibitor, wortmannin (10 nmol/l; Calbiochem); a MAP kinase activator (selective for the JNK and p38 family of MAP kinase); anisomycin (10 nmol/l-10 µmol/l; Calbiochem) and nitric oxide synthase (NOS) inhibitors: N G -Nitro-L-arginine methyl ester hydrochloride (L-NAME) (30 µmol/l; Dojindo, Kumamoto, Japan) and N 5 -(1-Iminoethyl)-L-ornithine dihydrochloride (L-NIO) (3 µmol/l; Dojindo, Kumamoto, Japan). The doses of the second messenger inhibitors were determined from their IC 50 values.
Statistical analysis.
All experiments were performed in triplicate with four different endothelial cell preparations. All values are expressed as means ± SEM. Data were analysed using a one-way ANOVA with a Fisher's Exact test for multiple comparisons. A p value of less than 0.05 was considered significant.
Results

Effect of high insulin on PMN migration across HUVEC.
To establish the optimum concentration of insulin for stimulating PMN migration across HUVEC monolayers, dose-response and time-response experiments were carried out. HUVEC monolayers were incubated for 24 to 72 h with human regular insulin at doses from 10 to 500 µU/ml (0.0609 to 3.05 nmol/l). Insulin concentrations over 50 µU/ml (0.305 nmol/l) for 24 h or 100 µU/ml (0.609 nmol/l) for 48 to 72 h increased the migration of PMN obtained from healthy subjects in a dose-dependent (but not time-dependent) manner (Fig. 1) . The effects of high insulin reached a maximum at 24 h. In addition, the migration of PMN from diabetic patients (n=4) with hyperinsulinaemia through HUVEC incubated with 100 µU/ml insulin for 24 h was increased compared with that from healthy subjects (healthy subjects: 28.2±0.7%; diabetic patients: 33.8±0.3%, ### p<0.001 compared with healthy subjects). The average insulin concentration of these diabetic patients was 107.3±7.5 µU/ml. Next, we examined whether high insulin concentrations promote endothelial cell proliferation and found that endothelial cell counts did not change after treatment with 100 µU/ml insulin for 24 to 72 h.
Effect of high insulin on surface expression of endothelial PECAM-1. We then evaluated whether high insulin influences the surface expression of the endothelial adhesion molecule, PECAM-1, and found that it was increased by incubating HUVEC with 100 µU/ml insulin only for 24 h (Fig. 2) . Since PMN migration across HUVEC and PECAM-1 expression mediated by high insulin reached their peaks at 24 h, in further experiments endothelial cells were incubated with 100 µU/ml insulin for 24 h. Addition of an antibody (Ab) specific for PECAM-1 (10 µg/ml) during the migration assay attenuated the enhanced PMN migration across HUVEC mediated by 100 µU/ml insulin for 24 h (Fig. 3A) , whereas anti-ICAM-1 Ab, anti-E-selectin Ab and anti-P-selectin Ab (10 µg/ml) did not affect the migration (Fig. 3B) . These results show a correlation between high insulinmediated PMN migration and over-expression of endothelial PECAM-1 but not of ICAM-1, E-selectin or P-selectin.
Effect of high insulin on endothelial PECAM-1 phosphorylation.
To assess why PMN migration mediated by high insulin was increased without enhancing PECAM-1 surface expression after 48 h, we analysed the change of PECAM-1 phosphorylation of HUVEC at different time points using a Western blotting method. However, in this study, we did not detect PECAM-1 phosphorylation at any points in cells treated with or without 100 µU/ml insulin until 72 h, suggesting that PECAM-1 phosphorylation was irrelevant to the increased PMN migration.
Effects of intracellular second messenger inhibitors on the high insulin-mediated PMN migration and PECAM-1 expression.
We attempted to define the signal transduction pathways involved in the enhanced PMN migration mediated by high insulin. The enhanced migration caused by 100 µU/ml insulin for 24 h was attenuated by a tyrosine kinase inhibitor, genistein (5 µmol/l) (Fig. 4A) , but not by a classic PKC inhibitor, Gö6976 (10 nmol/l) (Fig. 4B) , a broad PKC inhibitor, Gö6983 (0.1 µmol/l), a PKA inhibitor, H-89 (0.1 µmol/l) (Fig. 4C) , a PKG inhibitor, KT5823 (0.5 µmol/l), or an intracellular calcium chelator, TMB-8 (0.1 mmol/l) (Fig. 4A) .
We also examined the participation of two insulin receptor-mediated tyrosine kinases, MAP kinase and PI-3 kinase, in the action of high insulin on PMN migration, and found that a MAP kinase inhibitor, PD98059 (10 µmol/l), but not a PI-3 kinase inhibitor, wortmannin (10 nmol/l), attenuated the effect of high insulin (Fig. 4D) .
The enhanced expression of endothelial PECAM-1 caused by 100 µU/ml insulin for 24 h was also inhibited by the tyrosine kinase inhibitor, genistein (5 µmol/l) (Fig. 5A ) and the MAP kinase inhibitor, PD98059 (10 µmol/l) (Fig. 5B) .
Participation of MAP kinase activation in PMN migration and endothelial PECAM-1 expression.
To confirm the participation of MAP kinase activation in both PMN migration and endothelial PECAM-1 expression, we examined the effects of a MAP kinase activator, anisomycin. Anisomycin, in concentrations over 1 µmol/l, by itself increased PMN migration and in concentrations over 0.1 µmol/l enhanced surface expression of endothelial PECAM-1 within 3 h in a dose-dependent manner (Fig. 6A, B) , suggesting the involvement of MAP kinase in these phenomena.
Effects of NOS inhibitors on the enhanced PMN migration across HUVEC mediated by high insulin.
To see if there is a relation between nitric oxide and the enhanced PMN transendothelial migration caused by high insulin, we examined the effects of two NOS inhibitors, an endothelial NOS inhibitor, L-NAME (30 µmol/l) and an inhibitor of inducible NOS, L-NIO (3 µmol/l). These NOS inhibitors did not affect the enhanced PMN migration mediated by 100 µU/ml insulin for 24 h (control: 33.5±0.5%; high insulin: 45.2±0.8%; high insulin + L-NAME: 44.3±0.9%; high insulin + L-NIO: 46.3±1.1%), suggesting that at least endogeneous nitric oxide was not involved in this phenomenon.
Discussion
We found evidence for the direct atherogenic actions of high insulin, which at concentrations over 50 µU/ml for 24 h or 100 µU/ml for 48 to 72 h, significantly enhanced neutrophil transendothelial migration in a dose-dependent manner. In addition, endothelial migration of PMN obtained from diabetic patients with hyperinsulinaemia was also increased compared with that from healthy subjects. The PMN transendothelial migration enhanced by high insulin might account for the high incidence of atherosclerotic diseases such as AMI and stroke in patients with diabetes, because PMN transendothelial migration seems to contribute to the formation of atherosclerotic plaques and their disruption [4, 13] . There is growing evidence supporting a close relation between atherosclerosis and PMN activation and migration [11, 12, 22, 23, 24, 25, 26, 27] . Firstly, atherosclerosis has been reported to be characterized by monocyte infiltration which can be mediated by the neutrophil-induced release of endothelial monocyte-chemoattractant protein-1 [22] . Secondly, some investigators suggested that the activity of MPO, which is an enzyme from leukocytes including neutrophils, was correlated with the presence of AMI, and MPO itself was present in atherosclerotic plaques [12, 23] . Thirdly, recent reports indicated that neutrophils are occasionally found in disrupted plaques and also that they migrate into the arterial wall shortly after ischaemia-reperfusion [11, 24] . Apoptosis of neutrophils after their transendothelial mi- Fig. 5A, B . Effects of tyrosine kinase inhibitors on the high insulin-mediated PECAM-1 expression. Cells were treated without (control) or with 100 µU/ml insulin for 24 h (insulin) in the presence or absence of a tyrosine kinase inhibitor, 5 µmol/l genistein (A), and a MAP kinase inhibitor, 10 µmol/l PD98059 (B). Values are expressed as means ± SEM. ***p<0.001 compared to respective control, ## p<0.01 compared to the cells treated with high insulin alone Fig. 6A, B . Effects of a MAP kinase activator, anisomycin on PMN migration (A) and endothelial PECAM-1 expression (B). Cells were treated without (control) or with anisomycin at doses ranging from 0.01 to 10 µmol/l for 3 h. Values are expressed as means ± SEM. **p<0.01, ***p<0.001 compared to respective control gration seems to be crucial for the progression of atherosclerotic plaques because their delayed apoptosis after migration results in the maintenance of oxygen radicals and chemoattractant release leading to enhanced cytotoxicity and subsequent tissue damage, that predispose to cause plaque disruption [25, 26, 27] .
Since PMN transendothelial migration is modulated by endothelial adhesion molecules, especially by PECAM-1 [14, 15] , we hypothesized that the enhanced migration caused by high insulin was secondary to the induction of the adhesion molecule on insulin-activated endothelial cells. We found that the enhanced PMN migration observed for 24 h of incubation with high insulin (100 µU/ml) was associated with a concomitant increase in the expression of endothelial PECAM-1. The involvement of endothelial PECAM-1 in insulin-enhanced PMN migration was confirmed by showing that it was inhibited by an anti-PECAM-1 Ab but not by an anti-ICAM-1, anti-Pselectin or anti-E-selectin Ab. We reported previously that high insulin increased endothelial ICAM-1 expression leading to enhanced neutrophil-endothelial cell adhesion [20] ; however, it is not likely that ICAM-1 expression is correlated with PMN transendothelial migration. We found that high insulin directly enhanced endothelial PECAM-1 expression leading to increased PMN transendothelial migration, whereas many reports have indicated that surface expression of endothelial PECAM-1 is not altered by inflammatory mediators [14, 28] . Conversely, ICAM-1 and E-selectin were reported to have roles in transendothelial migration of lymphocytes and eosinophils [29, 30] .
The question arises as to why the high insulinmediated PMN migration increased until 72 h while endothelial PECAM-1 surface expression was enhanced only within 24 h. We hypothesized that the increased PMN migration after 48 h in our model could be attributed mainly to enhanced PECAM-1 phosphorylation but not to the increase in its surface expression, since previous studies suggested that enhanced PECAM-1 phosphorylation without enhanced endothelial PECAM-1 expression could increase PMN migration [31, 32] . However, in this study, we found that PECAM-1 phosphorylation was not enhanced at any points in cells treated with or without 100 µU/ml insulin until 72 h, suggesting that PECAM-1 phosphorylation was irrelevant to the increased PMN migration. Therefore, it is possible that PMN migration enhanced by high insulin after 48 h is correlated with another mechanism. In addition to PECAM-1, leukocyte transmigration has been reported to be modulated by some junctional proteins between endothelial cells such as vascular endothelial (VE)-cadherin, junctional adhesion molecule (JAM)-1 and CD 99 [33, 34, 35] . Another study indicated that reactive oxygen species (ROS) such as hydrogen peroxide are involved in PECAM-1-dependent leukocyte transmigration [31, 32, 36] . In this regard, a possible explanation of the discrepancy between PMN migration and PECAM-1 expression data after 48 h is that high insulin might enhance PMN migration affecting such junctional proteins or ROS. Therefore, further experiments in this study used only cells incubated with 100 µU/ml insulin for 24 h.
We then investigated the intracellular signal transduction pathways which could be involved in the enhanced PMN migration and endothelial PECAM-1 expression mediated by high insulin. Of the second messenger inhibitors tested, only a tyrosine kinase inhibitor, genistein, attenuated the effects of high insulin, suggesting the involvement of this pathway in our model. We further evaluated the correlation of insulin receptor-mediated two tyrosine kinases, MAP and PI-3, with the insulin-mediated enhanced PMN migration and endothelial PECAM-1 expression, because it has been reported that an imbalance between these two pathways in diabetes could be the cause of accelerated atherosclerosis in patients with diabetes [37] . We found that both the high insulin-mediated PMN migration and endothelial expression were attenuated by pretreatment with the MAP kinase inhibitor, PD98059, but not with the PI 3-kinase inhibitor, wortmannin. In addition, a MAP kinase activator, anisomycin, by itself increased both PMN migration and endothelial PECAM-1 expression. These findings strongly suggest that high insulin enhances both events via activation of a MAP kinase pathway. Although little is known about the intracellular mechanisms responsible for high insulin-mediated PMN migration, previous studies demonstrating that insulin promotes vascular smooth muscle cell migration leading to acceleration of atherosclerosis through tyrosine kinase activity, particularly that of MAP kinase, might support our results [38, 39] . In addition, consistent with our data, a recent study suggested the involvement of MAP kinase signalling in monocyte migration, because transmigration of monocytes mediated by monocyte chemoattractant protein (MCP)-1 was attenuated by PD98059 [9] .
Although a normal concentration of insulin induces endothelium-derived nitric oxide [40] , which is one of the most important anti-inflammatory mediators, this is reported to be blunted in insulin resistance [41, 42] . This is caused by decreased synthesis of nitric oxide from the endothelium and along with the insensitivity of vascular endothelial cells to nitric oxide results in the promotion of vascular inflammation [43, 44] . We therefore examined the correlation between nitric oxide and the enhanced PMN migration mediated by high insulin by using NOS inhibitors. However, the addition of two different NOS inhibitors, L-NAME and L-NIO, did not modify the results, suggesting that at least endogenous nitric oxide did not participate in the high insulin-mediated effects.
Our study clarifies the direct atherogenic action of high insulin on the endothelium which involves enhanced neutrophil transendothelial migration through an increase in surface expression of endothelial PECAM-1. These phenomena are mediated by activation of a tyrosine kinase pathway, especially MAP kinase, without the participation of endogenous nitric oxide. These results should facilitate the development of better pharmacologic agents to prevent vascular complications in patients with diabetes, particularly those with hyperinsulinaemia.
